Flutamide PBPK Model
Indication: Stage D2 metastatic prostate cancer (combined with LHRH agonist)
Interactive PBPK-derived pharmacokinetic simulator for flutamide and its active metabolite 2-OH-flutamide. Based on Sharma et al. (2020) whole-body PBPK model calibrated to Radwanski et al. (1989) human data. Explore CYP1A2-driven metabolism, tissue partition coefficients (Kp prostate/plasma = 2.17), and parent-metabolite PK for prostate cancer dosing (250 mg TID).
Drug Overview
Clinical Context
- Molecular Target
- Androgen Receptor (AR)
- Drug Class
- Non-steroidal Antiandrogen
- Therapeutic Area
- Oncology / Prostate Cancer
- Indication
- Stage D2 metastatic prostate cancer (combined with LHRH agonist)
- Route of Administration
- Oral
Model Information
- Model Type
- PBPK-Derived Parent-Metabolite (1-CMT per species)
- Reference
- Sharma et al. (2020) Environ Res; Radwanski et al. (1989) Clin Pharmacol Ther
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pharmacokinetic Parameters
PK Parameters
| Parameter | Value |
|---|---|
| ka | 1.5-2.5 h⁻¹ |
| CL F | 25-35 L/h |
| Vc F | 60-80 L |
Additional Parameters
| Parameter | Value |
|---|---|
| dose | 250 mg TID |
Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.
About This Simulator
This interactive pharmacokinetic simulator for Flutamide PBPK Model allows you to explore concentration-time profiles under different dosing scenarios. The underlying PBPK-Derived Parent-Metabolite (1-CMT per species) model characterizes the pharmacokinetics of this non-steroidal antiandrogen following oral administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Flutamide PBPK Model PK simulator?
This is a free, interactive pharmacokinetic simulator for Flutamide PBPK Model used in Stage D2 metastatic prostate cancer (combined with LHRH agonist). It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Flutamide PBPK Model belong to?
Flutamide PBPK Model is classified as a Non-steroidal Antiandrogen that targets Androgen Receptor (AR). It is used in the Oncology / Prostate Cancer therapeutic area.
What route of administration does this model simulate?
This simulator models Oral administration of Flutamide PBPK Model. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a PBPK-Derived Parent-Metabolite (1-CMT per species) model. PBPK models use physiological parameters to predict drug distribution across tissues and organs.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
What is the half-life of Flutamide PBPK Model?
Based on the published model parameters, the elimination half-life of Flutamide PBPK Model is approximately 5-6 hours (flutamide). Note that half-life can vary based on patient-specific factors such as body weight, organ function, and genetic polymorphisms.
What is the clearance of Flutamide PBPK Model?
The clearance (CL) of Flutamide PBPK Model is approximately 25-35 L/h. Clearance represents the volume of plasma from which drug is completely removed per unit time and is a key determinant of drug exposure and steady-state concentrations.
Ready to Simulate?
Launch the Flutamide PBPK Model simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community